Some ACR members will be randomly selected to take an important survey to determine relative values for services in new outpatient consultation codes.
Medicare Contractors Provide Guidance for Use of JA, JB Modifiers
As of April 2021, Medicare requires the use of the JA or JB modifier when billing for drugs that have one Healthcare Common Procedure Coding System Level II (J or Q) code but multiple routes of administration.
10 Tips to Master E/M Coding Changes
Learn to properly use the revised CPT codes to document your time and medical decision making during patient visits to help ensure your practice is appropriately remunerated.
ACR Offers Evaluation & Management Coding Lunch & Learn Series
ACR practice management staff are offering a free, tailored, one-hour Lunch & Learn series to help members, practices and their staff become familiar with new office and outpatient evaluation and management codes and documentation guidelines that went into effect Jan. 1.
UnitedHealthcare Designates Avsola, Inflectra Preferred Infliximab Products
On Feb. 1, UnitedHealthcare enacted a new policy designating Avsola and Inflectra as the preferred infliximab products for UHC commercial plans. ACR leaders have urged UHC to allow existing patients to continue on their current medication.
A New Era of Coding Evaluation & Management Services
After 25 years, the American Medical Association (AMA) Current Procedural Terminology (CPT) office and outpatient evaluation and management (E/M) codes received a major overhaul. These changes, which went into effect Jan. 1, will help reduce administrative burden on providers and roll back some of the rigid requirements for E/M coding by simplifying the code selection…
Evaluation & Management Coding Changes in the 2021 Physician Fee Schedule Final Rule
Implementation of rate increases for evaluation and management services and other changes bring big updates to many Current Procedural Terminology codes.
UHC Updates Rituximab Policy to Require Use of Biosimilars
As of Oct. 1, UnitedHealthcare (UHC) requires that patients fail to respond to both FDA-approved rituximab biosimilars prior to receiving approval for rituximab. Exception: Rituximab-pvvr (Ruxience) is not FDA approved for rheumatoid arthritis.
ACR Convergence 2020 Workshop Covers 2021 Practice Management & Coding Changes
Attendees at the daylong workshop will learn about key evaluation and management code changes coming in 2021 that affect rheumatologists and rheumatology professionals.
Changes in ICD-10 for Sjögren’s Syndrome
A code change in the ICD-10 classification for Sjögren’s syndrome was approved by the ICD-10 Coordination and Maintenance Committee in July 2019 and becomes effective October 2020.
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 56
- Next Page »